Table 1 Treatments received by newly-referred adult CFS/ME patients across CFS/ME specialist services

A

Treatment data available, N = 126

4 (2–8), mean 5.6

6 (3–13), mean 8.2

2 (1–4), mean 3.1

4 (4–12), mean 8.0

With follow-up data (64/126 (50.8%))

5 (2–8), mean 5.4

6 (4–13), mean 7.9

2 (1–4), mean 3.1

4 (4–12), mean 7.8

Discharged before follow-up (41/64 (64.1%))

3 (1–5), mean 3.7

5 (1–9), mean 5.8

1 (1–2), mean 2.0

4 (4–12), mean 7.2

B

Treatment data available, N = 55

6 (2–10), mean 7.1

6 (2–13), mean 9.5

6 (4–7), mean 6.2

18 (7–24), mean 16.8

With follow-up data (23/55 (41.8%))

7 (3–12), mean 8.2

7 (3–15), mean 10.7

7 (5–8), mean 7.2

18 (18–28), mean 19.7

Discharged before follow-up (5/23 (21.7%))

5 (4–5), mean 5.0

5 (4–5), mean 5.0

5 (4–5), mean 5.0

-

C

Treatment data available, N = 22^b

11 (9–12), mean 10.0

19 (17–21), mean 18.4

1 (1–2), mean 1.7

18 (16–20), mean 16.8

Discharged before follow-up (7/22 (31.8%))

9 (7–11), mean 9.0

17 (13–21), mean 17.0

1 (1–1), mean 1.8

16 (10–20), mean 15.1

D

Treatment data available, N = 42

5 (2–8), mean 5.1

4 (3–6), mean 4.7

3 (2–6), mean 4.2

-

With follow-up data (25/42 (59.5%))

7 (4–8), mean 6.3

6 (4–7), mean 5.7

5 (3–7), mean 5.1

-

Discharged before follow-up (13/25 (52.0%))

7 (3–8), mean 6.2

5 (4–7), mean 5.6

4 (3–6), mean 4.8

-

E

Treatment data available, N = 133

6 (4–7), mean 5.6

6 (4–7), mean 5.9

6 (3–7), mean 5.4

11 (6–12), mean 9.7

With follow-up data (83/133 (62.4%))

6 (4–7), mean 5.9

6 (4–7), mean 6.1

6 (4–7), mean 5.8

11 (11–11), mean 11.1

Discharged before follow-up (26/83 (31.3%))

7 (4–7), mean 5.8

7 (4–8), mean 6.2

6 (3–7), mean 5.5

11 (11–14), mean 11.5

F

Treatment data available, N = 78

13 (9–14), mean 11.7

15 (10–18), mean 13.9

6 (5–11), mean 7.4

6 (1–13), mean 6.6

With follow-up data (58/78 (74.4%))

13 (11–15), mean 12.7

17 (13–18), mean 15.2

7 (5–12), mean 8.3

8 (1–13), mean 7.2

Discharged before follow-up (27/58 (46.6%))

12 (6–13), mean 10.3

16 (7–18), mean 12.9

5 (5–9), mean 5.8

10 (1–13), mean 7.7

G

Treatment data available, N = 25

12 (8–21), mean 13.0

12 (7–22), mean 13.8

12 (7–17), mean 13.2

8 (1–15), mean 7.5

With follow-up data (7/25 (28.0%))

11 (8–25), mean 14.4

10 (8–31), mean 16.3

10 (8–17), mean 14.2

15 (n = 1)

Discharged before follow-up (4/7 (57.1%))

11 (8–18), mean 12.8

10 (7–21), mean 14.0

10 (7–13), mean 10.4

15 (n = 1)

H

Treatment data available, N = 133

5 (1–9), mean 5.7

No data

No data

No data

With follow-up data (60/133 (45.1%))

6 (2–11), mean 6.8

No data

No data

No data

Discharged before follow-up (19/60 (31.7%))

6 (5–9), mean 7.0

No data

No data

No data

I

Treatment data available, N = 50

7 (2–10), mean 6.3

9 (3–15), mean 9.1

1 (0.3–6), mean 3.0

14 (8–16), mean 12.2

With follow-up data (26/50 (52.0%))

9 (5–11), mean 7.9

13 (7–16), mean 11.8

0.3 (0.3–4), mean 2.6

14 (10–17), mean 13.6

Discharged before follow-up (4/26 (15.4%))

5 (1–7), mean 4.0

5 (1–7), mean 4.0

7 (2–7), mean 5.3

-

J

Treatment data available, N = 47^#

5 (3–11), mean 6.4

4 (3–14), mean 8.7

2 (2–3), mean 2.8

2 (2–2), mean 7.0

Discharged before follow-up (23/47 (31.8%))

3 (2–4), mean 3.2

3 (2–4), mean 2.9

2 (1–3), mean 1.9

2 (2–2), mean 1.4

K

Treatment data available, N = 31

12 (10–13), mean 11.8

20 (16–23), mean 18.2

3 (2–5), mean 3.8

18 (14–20), mean 17.0

With follow-up data (20/31 (64.5%))

12 (10–15), mean 12.9

20 (17–24), mean 19.1

3 (2–6), mean 3.7

17 (16–20), mean 17.1

Discharged before follow-up (9/20 (45.0%))

12 (9–13), mean 10.4

18 (17–23), mean 17.7

2 (2–3), mean 2.5

16 (15–21), mean 17.2